In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients

被引:15
作者
Guezel, Cagla Bozkurt [1 ]
Gerceker, A. Alev [1 ]
机构
[1] Istanbul Univ, Fac Pharm, Dept Pharmaceut Microbiol, TR-34116 Istanbul, Turkey
关键词
cystic fibrosis; Pseudomonas aeruginosa; colistin methanesulfonate; antibiotic combinations;
D O I
10.1159/000119741
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The in vitro activities of various antibiotics, either alone or in combination with colistin methanesulfonate, were assessed using Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Methods: Except for colistin methanesulfonate, minimum inhibitory concentrations were determined by microbroth dilution technique as described by the Clinical and Laboratory Standards Institute ( CLSI); for colistin methanesulfonate, a modified method of the CLSI was used. Minimum bactericidal concentrations were determined as described by the CLSI. The in vitro activities of antibiotics in combination were determined by microbroth checkerboard technique, and results were interpreted by fractional inhibitory concentration index. Results: According to MIC values, 100, 98, 96 and 84% of the isolates were found susceptible to amikacin, colistin methanesulfonate, meropenem and ceftazidime, respectively. The minimum bactericidal concentrations were generally equal to or twice as high as those of the minimum inhibitory concentrations. With a fractional inhibitory concentration index of <= 0.5 as borderline, synergistic interactions were more frequent with combinations where amikacin was involved than with those with colistin methanesulfonate. No antagonism was observed. Conclusion: The findings of this study may play a useful role in selecting the appropriate combinations when a single agent is inadequate to treat cystic fibrosis patients with P. aeruginosa infections. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:147 / 151
页数:5
相关论文
共 24 条
[1]   PER-1- and OXA-10-like β-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey [J].
Aktas, Z ;
Poirel, L ;
Salcioglu, M ;
Özcan, PE ;
Midilli, K ;
Bal, Ç ;
Ang, Ö ;
Nordmann, P .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (03) :193-198
[2]  
[Anonymous], [No title captured]
[3]   Current guidelines for the treatment of severe pneumonia and sepsis [J].
Bodmann, KF .
CHEMOTHERAPY, 2005, 51 (05) :227-233
[4]   ROLES OF RIBOSOMAL-BINDING, MEMBRANE-POTENTIAL, AND ELECTRON-TRANSPORT IN BACTERIAL UPTAKE OF STREPTOMYCIN AND GENTAMICIN [J].
BRYAN, LE ;
KWAN, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (06) :835-845
[5]   CLINICAL-EVALUATION OF MEROPENEM VERSUS CEFTAZIDIME FOR THE TREATMENT OF PSEUDOMONAS SPP INFECTIONS IN CYSTIC-FIBROSIS PATIENTS [J].
BYRNE, S ;
MADDISON, J ;
CONNOR, P ;
DOUGHTY, I ;
DODD, M ;
JENNEY, M ;
WEBB, AK ;
DAVID, TJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 :135-143
[6]   A reassessment of the in-vitro activity of colistin sulphomethate sodium [J].
Catchpole, CR ;
Andrews, JM ;
Brenwald, N ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) :255-260
[7]  
*CLSI, 2006, M7A7 WAYN CLSI
[8]   OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa [J].
Danel, F ;
Hall, LMC ;
Duke, B ;
Gur, D ;
Livermore, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1362-1366
[9]   Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis:: a European consensus [J].
Döring, G ;
Conway, SP ;
Heijerman, HGM ;
Hodson, ME ;
Hoiby, N ;
Smyth, A ;
Touw, DJ .
EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (04) :749-767
[10]  
Frederiksen B, 1997, PEDIATR PULM, V23, P330, DOI 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO